New vaccine combo aims to clear persistent HPV infection
NCT ID NCT03913117
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests two vaccines designed to help the immune system fight HPV16, a virus linked to cervical cancer. The study includes 30 women with persistent HPV16 infection and mild cervical cell changes (ASC-US or LSIL). Participants receive a DNA vaccine followed by a protein vaccine boost, with the main goals being safety and finding the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pNGVL4aCRTE6E7L2 DNA vaccine and TA-CIN protein vaccine
- What this could lead to
- If successful, this could lead to a therapeutic vaccine that helps the immune system clear persistent HPV16 infection, potentially preventing progression to cervical cancer.
- What could go wrong
- This is a very early Phase 1 trial with only 30 participants, focused on safety and dosing. The vaccines may not produce a strong enough immune response to clear the virus, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASC-US are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21231, United States
-
UAB | The University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35249, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.